<DOC>
	<DOCNO>NCT01204372</DOCNO>
	<brief_summary>GATE 1 open-label , non-comparative , multicentric study evaluate efficacy tolerance combine use Gemcitabine , Trastuzumab Erlotinib first-line chemotherapy metastatic pancreatic cancer patient . The patient treat intravenously Gemcitabine dose 1000 mg/m2 30 min . For first eight week , Gemcitabine administer weekly 7 week follow one week rest . Subsequently , Gemcitabine administer weekly three week follow one week rest . Trastuzumab administer week dose 4 mg/kg 90 min . D1 2 mg/kg 30 min . subsequent infusion . Erlotinib administer orally dose 100 mg/day C1D1 . The patient subject research EGFR , HER2 KRAS status .</brief_summary>
	<brief_title>Trial Evaluating Combined Chemotherapy Patients With Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Metastatic pancreatic adenocarcinoma confirm histology Tumor sample available Measurable lesion accord RECIST criterion Performance status ≥ 1 Life expectancy &gt; 3 month Hematology : Hb ≥ 9g/dL , neutrophil ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 Renal function : creatinine ≤ 1.5 x ULN Hepatic function : total bilirubin ≤ 2.5 x ULN , transaminases ≤ 5 x ULN Left ventricular ejection fraction ( LVEF ) ≥ 50 % At least 6month delay end previous gemcitabinebased chemotherapy diagnosis metastasis Social security Informed consent obtain prior inclusion . Non metastatic advance local disease Presence cerebral metastasis symptomatic leptomeningeal carcinomatosis Others cancer except BBC cervical cancer receive curative treatment No previous treatment Erlotinib Trastuzumab Known severe hypersensitivity Erlotinib , Trastuzumab , murine protein Gemcitabine Presence significant comorbidities Concomitant treatment experimental product anticancer therapy Breastfeeding pregnant female , patient reproductive age use adequate contraception Legal incapacity limit legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Metastatic pancreatic adenocarcinoma</keyword>
	<keyword>First-line chemotherapy</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>Targeted agent</keyword>
</DOC>